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ABSTRACT: Glycosylation signiﬁcantly alters the biological
and physicochemical properties of small molecules. β-Lactam
alcohols comprise eligible substrates for such a transformation
based on their distinct relevance in the chemical and
medicinal community. In this framework, the unprecedented
enzymatic glycosylation of the rigid and highly strained four-
membered β-lactam azaheterocycle was studied. For this
purpose, cis-3-hydroxy-β-lactams were eﬃciently prepared in
three steps by means of a classical organic synthesis approach,
while a biocatalytic step was implemented for the selective formation of the corresponding 3-O-α- and -β-glucosides, hence
overcoming the complexities typically encountered in synthetic glycochemistry and contributing to the increasing demand for
sustainable processes in the framework of green chemistry. Two carbohydrate-active enzymes were selected based on their
broad acceptor speciﬁcity and subsequently applied for the α- or β-selective formation of β-lactam-sugar adducts, using sucrose
as a glucosyl donor.
■ INTRODUCTION
The very ﬁrst β-lactam synthesis by Staudinger back in 1907,1
followed by the accidental discovery of the antibacterial
properties of penicillin 1 (penicillin G, R = Bn) by Fleming 20
years later,2 marked the beginning of a revolution in the
science of medicine (Figure 1). Up to now, penicillins and
more recently discovered classes of β-lactam antibiotics are
considered to be the major means of defense against
pathogenic bacteria and represent the world’s major bio-
technology products.3 Over the years, besides their anti-
bacterial properties, other pharmacological features of β-
lactams were also unveiled (e.g., cholesterol absorption
inhibition,4 inhibition of human tryptase,5 thrombin6 and
chymase,7 vasopressin V1a antagonist activity,8 antiviral,9
antitumor,10 antidiabetic,11 anti-inﬂammatory,12 antiparkinso-
nian13 and antitubercular activity,14 etc.), which, in combina-
tion with their considerable synthetic importance as four-
membered, highly strained cyclic amides,15,16 promoted β-
lactams to become one of the most studied classes of
azaheterocycles to date.
In general, monocyclic β-lactams unfairly comprise an
underexplored subclass, though they are particularly interesting
with respect to the treatment of bacterial infections (e.g.,
commercial 3-aminomonobactam aztreonam 2, Figure 1).17 3-
Hydroxy-β-lactams 3, such as glutamine synthetase-inhibiting
tabtoxinine β-lactam 4, can also possess antimicrobial
activity,18,19 whereas others have been proven to exhibit
signiﬁcant antitumor eﬀects. For example, several 1,4-diary-
lazetidin-2-ones (such as compound 5), which are conforma-
tionally restricted analogues of (Z)-combretastatin A-4 6, a
natural product that inhibits tubulin polymerization, showed
strong potencies against human neuroblastoma cell growth.10
Furthermore, the renowned “β-lactam synthon method” has
been applied repeatedly to convert versatile 3-hydroxy-β-
lactam precursors into a variety of highly functionalized
scaﬀolds of biological and medicinal interest,15 such as the side
chain of the anticancer drug taxol,20 antibiotics,21 alkaloids,22
amino acids, peptides,23 etc.
In the framework of the biological and synthetic relevance of
the class of 3-hydroxy-β-lactams (3, Figure 1), we proposed to
subject them to a glucosylation reaction, i.e. glycosylation with
glucose.24 Glycosylation can be deﬁned as the attachment of a
carbohydrate onto a chemical scaﬀold, known as the aglycone,
via an O-, N-, S-, or C-atom. Hence, in this study, the β-lactam
3-hydroxy-entity serves as the anchor point. Glycosylation is a
very common phenomenon in nature and probably concerns
one of the most frequent and important modiﬁcations of
biomolecules.25 It is, for instance, believed to play a key role in
cellular communication in plants through accumulation,
storage, and transport of hydrophobic substances.26 Moreover,
glycosylation has numerous practical applications in synthesis,
where it might act as a chiral source or lead to bioactive
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precursors,27−29 or in industry, where it can be applied to
detergents and cosmetics (e.g., long alkyl chain aglycones),30,31
antifungal and antimicrobial compounds (e.g., unsaturated
alkyl chain aglycones),32 antitumor formulations and cardiac-
related drugs (e.g., peptide and steroid aglycones)32,33 and
“controlled release” compounds (e.g., ﬂavor and fragrance
aglycones).34
This endless series of examples arises from the inﬂuence
glycosylation can exert on various physicochemical and
biological properties. The most obvious advantage concerns
the solubility and bioavailability increase of hydrophobic
aglycones, augmenting their potential in pharmacological
applications,24 as is for example the case for glycopeptides
and curcumin (20 million-fold better aqueous solubility of the
latter).35,36 Besides the eﬀect on solubility, glycosylation can be
used to alter the bioactivity of the compound. Although so far
not a widespread mechanism of antibiotic resistance,
glycosylation does play a role in self-protection of antibiotic-
producing organisms,37 while bringing about a spectacular
increase in activity, as is well illustrated by vancomycin, a
glycopeptide eﬀective against methicillin-resistant Staphylococ-
cus aureus. By means of glycorandomization, which is a way to
acquire a library of analogues by changing the carbohydrate
moiety, several derivatives have been found to be up to 500
times more eﬀective than vancomycin itself.38 Related to this,
and even more triggering for the purpose of this study, is the
ﬁnding that phenolic O-glycosylated ezetimibe, a β-lactam with
cholesterol absorption inhibitory activity, was found to be 4
times as potent as its corresponding aglycone 7 (Figure 2).39
Moreover, glycosylation enables tuning of the oxidative and
thermal stability, as is the case for vitamin C,40 or the toxicity
of the aglycone, illustrated by a reduced cardiotoxicity of
anthracycline antibiotics.41
Undoubtedly, glycosides are of high commercial interest,26
though their synthesis is still far from trivial. Chemical
glycosylation reactions using these complex substrates typically
suﬀer from the lack of regioselectivity (primary, secondary, and
hemiacetalic hydroxyl groups) and stereoselectivity with
respect to the anomeric carbon center. Protection and
deprotection steps have to be taken into account, involving
additional synthetic manipulations, reagents, catalysts, solvents
and hence toxic chemical waste streams, besides low overall
yields. The development of economically and ecologically
feasible procedures in the ﬁeld of glycochemistry thus remains
challenging.24,25,42 Biocatalytic routes have therefore received
increasing attention as eﬃcient and green alternatives, by
circumventing the disadvantages associated with chemical
glycosylation protocols.43,44 Enzymes are capable of regio-,
stereo-, and enantioselectively glycosylating various acceptors
under mild conditions using renewable starting materials,
rendering additional synthetic steps and the concomitant
requirements redundant. However, despite considerable eﬀorts
to improve enzymatic glycosylation reactions, no universal
enzymatic glycosylation platform exists to date. Furthermore,
the methodology still suﬀers from the lack of long-term
enzymatic stability, acceptor solubility issues in the aqueous
systems used and mostly expensive donors, hence hampering
its broad use.24,45,46
Yet, convinced by the assets of biocatalysis and its
implementation in organic synthesis, as was also demonstrated
by our preliminary studies on the chemoenzymatic syntheses
of biologically relevant azaheterocyclic compounds,47,48 the
enzymatic glucosylation of chemically prepared cis-3-hydroxy-
β-lactams 8, without aﬀecting the sensitive four-membered ring
system, is envisioned in the current work. In fact, enzymatic
glycosylation of 3-hydroxy-β-lactams as challenging substrates
based on their rigidity and steric bulk, has never been
described before. As the conﬁguration of the anomeric center
is known to alter the biological properties of the molecule,49,50
the selective formation of both α- and β-glucosides 9 are
contemplated, as presented in Scheme 1.
■ RESULTS AND DISCUSSION
In a ﬁrst phase, the selective synthesis of the starting cis-3-
hydroxy-β-lactams 8 was performed based on preceding
research performed by our group, by means of three
consecutive steps.51 Though reported more than 100 years
ago, the Staudinger synthesis remains the most general and
most frequently applied methodology for the preparation of β-
lactams and derived compounds based on its simplicity in
reaction procedures and predictability of the stereochemical
outcome. The mechanism concerns a [2 + 2]-cyclocondensa-
tion between functionalized aldimines, obtained through
imination of the corresponding aldehydes, and in situ
generated ketenes.1 To that end, primary amines 11 were
condensed with aldehydes 10 in the presence of magnesium
sulfate under various conditions, depending on the nature of
the substrates (Scheme 2 and Table 1). The (E)-N-(alkyl/
Figure 1. Bioactive (β-lactam-containing) compounds.
Figure 2. Ezetimibe 7.
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arylmethylidene)amines 12, thus obtained were reacted with
acetoxyacetyl chloride 13, transformed in situ to the
corresponding ketene through treatment with triethylamine,
aﬀording 3-acetoxyazetidin-2-ones 14. The appropriate alkylic/
arylic starting materials were selected (R1 = iPr, Pr, Ph; R2 =
Bn, iPr), thus oﬀering a variety of β-lactams with respect to
steric bulk and polarity. Almost complete diastereoselectivity
toward the cis-β-lactams 14 was observed, as deduced from the
1H NMR spectra (CDCl3). The vicinal coupling constants
JH3−H4 between the C3- and C4-protons of the azetidin-2-one
ring systems varied between 4.6 and 5.0 Hz, values typical for
cis-isomers,52 while for derivative 14a, a minor amount (9%) of
trans-β-lactam was formed as well (JH3−H4 = 1.7 Hz, CDCl3).
Pure cis-β-lactams 14 were obtained after column chromatog-
raphy-mediated isolation on silica gel (except for alkyl-
derivative 14b, posing diﬃculties during puriﬁcation and
hence further used in a crude form) and subjected to alkaline
conditions in a mixture of methanol and water (1:1−2:1) for
deacetylation of the C3-group, thus releasing the premised free
alcohols 8 for subsequent glycosylation without aﬀecting the
relative cis-stereochemistry.
In the past century, organic chemists have developed various
methods to glycosylate diﬀerent acceptors, including hydroxy-
lated β-lactams. Banik and co-workers led this research ﬁeld
when it comes to 3-O-glycosylazetidin-2-ones, more speciﬁcally
the stereospeciﬁc glycosylation with glycals, cyclic enol ether
derivatives of sugars. They reported an iodine-catalyzed α-
glycosylation reaction of racemic 3-hydroxy-β-lactams with
various 3-acetoxyglycals via the Ferrier rearrangement,
providing access to an optically pure intermediate ((3R,4S)-
3-acetoxy-1-(p-anisyl)-4-phenylazetidin-2-one) for the prep-
aration of the Taxol and Taxotere side chain by means of the
optical resolution principle.53 Toward the same objective,
some research groups employed the Staudinger synthesis
starting from protected glycosylated precursors of ketenes,
equally aﬀording 3-O-β-lactam-sugar adducts containing
several chiral centers, which served as a source of chirality in
asymmetric synthesis.54−56
A variety of other chemical procedures are available enabling
coupling of a sugar entity with a β-lactam at the C3-, C4-, or
even the N1-position (or further away from the β-lactam
nucleus) through carbon−carbon or carbon−heteroatom bond
formation.57 However, as mentioned before, these reactions
typically suﬀer from low yields, low atom eﬃciencies, and
excessive burden on the environment, making them barely
viable from an economic and ecological point of view.
Nonetheless, to be able to compare a chemical and enzymatic
approach for the glucosylation of our speciﬁc substrates, the
classical Koenigs−Knorr glycosylation was tested in this study
for the attempted synthesis of 3-O-β-glucosyl-β-lactams 9.58
The mechanism comprises nucleophilic substitution of a
glycosyl halide by an alcohol and still constitutes a preferred
synthetic method in glycochemistry. Unfortunately, we
encountered various obstacles when testing several glucosyl
donors, acceptors, and reaction conditions, giving rise only to a
minor amount of the expected glycoside and hence conﬁrming
the general conclusions reported in the literature with respect
to chemical glycosylations.
On the other hand, many of the drawbacks of chemical
glycosylation may be overcome by using biocatalysts.
Scheme 1. α- and β-Glucosylation of cis-3-Hydroxy-β-lactams 8 by a Mutant Glycoside Phosphorylase from
Thermoanaerobacterium thermosaccharolyticum (TtSPP) or by a Glycosyltransferase from Stevia rebaudiana, Respectively
Scheme 2. Synthesis of 3-Hydroxyazetidin-2-ones 8
Table 1. Synthesis of 3-Hydroxyazetidin-2-ones 8
Cpd R1 R2 solvent, T 12 (%) eq 13, solvent, t 14 (%) (cis/trans)a MeOH/H2O 8 (%)
d (cis/trans)
10a iPr Bn THF, Δ 99 1.3 eq 13, CH2Cl2, 16 h 47b (91:9) 2:1 47 (100:0)
10b Pr iPr CH2Cl2, rt 90 1.1 eq 13, CH2Cl2, 16 h 84
c (100:0) 1:1 9e (100:0)
10c Ph Bn THF, Δ 99 1.5 eq 13, THF, 72 h 69b (100:0) 1:1 62 (100:0)
aDetermined via 1H NMR analysis of the crude reaction mixture. bAfter column chromatography (SiO2).
cCrude yield. dAfter recrystallization from
EtOAc/hexane (1:1). eOverall yield from imine 12b.
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Nakayama and co-workers developed the ﬁrst detailed
synthesis of vancomycin and some derivatives through two
enzymatic glycosylation steps,45 while the enzymatic glucur-
onidation of ezetimibe 7 has been reported by Zaks and
Dodds, in up to 92 and 88% isolated yield, respectively.59
Although the synthesis of the donor substrates is somewhat
demanding, careful comparison with their chemical syntheses,
requiring tedious protection−deprotection steps of the glycosyl
donors resulting in low overall yields, pointed to the enzymatic
approach to be the most eﬃcient one.39,60,61
Four types of enzymes that are capable of catalyzing a
glycosyl transfer can be distinguished (Scheme 3).62 The vast
majority of glycosylation reactions in nature is performed by
glycosyltransferases. Although these biocatalysts are highly
eﬃcient and provide excellent regio- and stereocontrol, their
practical use is hampered due to the excessive cost of the
nucleotide-activated carbohydrate donors they require. Trans-
glycosidases are an attractive alternative in this regard, using
cheap substrates such as sucrose and amylose, but the variety
of diﬀerent transglycosidase speciﬁcities that have been
reported to date is rather limited. Finally, glycoside hydrolases
and phosphorylases both perform a catabolic role in vivo,
cleaving glycosidic bonds using water or phosphate,
respectively, but they can be exploited for synthetic purposes
under speciﬁc process conditions as well.
A critical property to consider when choosing a suitable
candidate for catalyzing the envisioned glycosylation reactions
is the substrate promiscuity. Indeed, acceptor sites that are
strictly speciﬁc toward a narrow group of molecules will be less
likely to bind the rather challenging cis-3-hydroxy-β-lactam
targets. Therefore, two biocatalysts that are known to have a
broad acceptor scope were selected. The sucrose 6′-phosphate
phosphorylase from T. thermosaccharolyticum (TtSPP) is an
appealing enzyme for the synthesis of α-glucosides considering
the use of sucrose as a cheap and renewable donor substrate,
and shows activity on a diverse range of small molecules with
retention of the anomeric conﬁguration.63 Moreover, a mutant
of TtSPP (R134A) was rationally designed previously in our
laboratory to widen the entrance to the active site, triggering
aﬃnity for bulky polyphenols such as resveratrol.64 The
selected option for the synthesis of β-bonded adducts concerns
the stevioside glucosyltransferase from S. rebaudiana (UGT-
76G1Sr), which has been employed successfully on structures
such as branched alcohols, ﬂavonoids, terpenoids, and more.65
Although its need for the expensive donor substrate uridine
diphosphate glucose (UDP-glucose) is a major drawback, this
Scheme 3. Carbohydrate-Active Enzymes Used in Glycosylation Reactions (A = Acceptor; Pi = Inorganic Phosphate; UDP =
Uridine Diphosphate)24
Scheme 4. Enzymatic Glucosylation of 3-Hydroxy-β-lactams 8 (TtSPP_R134A, Mutant R134A of the Sucrose 6′-Phosphate
Phosphorylase from T. thermosaccharolyticum; UGT-76G1Sr, UDP-Glucosyltransferase from S. rebaudiana; SuSy, Sucrose
Synthase from Acidithiobacillus caldus)
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problem is circumvented in this work by coupling the reaction
to a sucrose synthase (SuSy).66 Hence, UDP-glucose is
regenerated from sucrose in situ while conveniently recycling
the UDP byproduct of the transferase reaction (Scheme 4).
The solubility of the β-lactam acceptors 8 is quite poor in
the aqueous solutions that these enzymes prefer. Therefore,
the performance of various cosolvents (10% v/v) was assessed
in small-scale glucosylation reactions. 2-Methylbutan-2-ol and
acetonitrile appeared to be toxic to the enzymes, while 2-
phenylethanol and isobutanol were unsuitable as they were
found to act as acceptor substrates as well, resulting in side
products. The desired glucoside was present in highest
quantity when diethyl ether, acetone, methanol, dimethyl
sulfoxide (DMSO), or methyl t-butyl ether were added.
Acetone was ﬁnally selected as the most appropriate cosolvent
due to its low toxicity, high volatility, and the absence of
potentially competing hydroxyl groups. Additionally, the
optimal acceptor concentration was determined for both the
α- and β-glucosylation reactions. The highest conversions were
observed at a concentration of 15 mM in all cases, except for
the reaction of 8a with TtSPP_R134A (21 mM).
The α- and β-glucosylation of all three β-lactam acceptors
were carried out at a preparative scale (0.375−2.1 mmol
acceptor 8) under these optimized conditions, at several
degrees below the enzymes’ optimal temperature to slow down
irreversible denaturation. All glucosides were successfully
synthesized, although the reactions proceeded very slowly
and took several days to reach a practical degree of conversion
(Table 2). As a comparison, almost complete conversion of
resveratrol could be achieved within 24 h with these
enzymes.63,64 This diﬀerence may be explained by the rigid
and bulky structure of the current compounds, which could
cause steric clashes in the active site. Finally, after inactivation
and removal of the enzymes, the target compounds 9 could be
recovered and puriﬁed by means of (a sequence of)
chromatographic techniques, which resulted in rather low
yields. However, it should be noted that the main focus of this
research was to obtain and isolate the glucosides in an
analytically pure form to allow their spectroscopic analysis,
hence the elaborate puriﬁcation procedures to remove all
impurities.
The successful synthesis of cis-3-O-D-glucopyranosyl-3-
hydroxyazetidin-2-ones 9-αG and 9-βG was conﬁrmed on
the basis of the characteristic spectral data and their
accordance with reported literature values (Scheme 4, Tables
2 and 3).67 The typical anomeric proton signals are located as a
doublet around δ 4.97−5.21 and 4.10−4.70 ppm for the α- and
β-glucosides, respectively, and can easily be distinguished from
the nearby doublet signals of the protons located on the β-
lactam ring (J = ±5 Hz) (1H NMR, D2O). A clear diﬀerence is
to be noticed between the respective values of the vicinal
coupling constants JH1−H2 between the anomeric H1 and its
Table 2. Enzymatic Glucosylation of 3-Hydroxyazetidin-2-ones 8
Cpd R1 R2 reaction conditions conversion (%)d 9 (%)
α-glucosylation
8a iPr Bn 21 mM 8a, 0.06 mg/mL TtSPP-R134A, 8 d 23 12a
8b Pr iPr 15 mM 8b, 0.04 mg/mL TtSPP-R134A, 22 d 50 17b
8c Ph Bn 15 mM 8c, 0.04 mg/mL TtSPP-R134A, 20 d 12 3b
β-glucosylation
8a iPr Bn 15 mM 8a, 0.13 mg/mL UGT-76G1Sr, 0.36 mg/mL SuSy, 6 weeks 9 0.2c
8b Pr iPr 15 mM 8b, 0.19 mg/mL UGT-76G1Sr, 0.31 mg/mL SuSy, 2 weeks 14 1.4c
8c Ph Bn 15 mM 8c, 0.11 mg/mL UGT-76G1Sr, 0.31 mg/mL SuSy, 2 weeks 4 1c
aAfter column chromatography (SiO2).
bAfter column chromatography (SiO2) and prep. thin-layer chromatography (TLC).
cAfter two-step
column chromatography (SiO2 & C18).
dDetermined via liquid chromatography−mass spectrometry (LC−MS)-analysis of the crude reaction
mixture.
Table 3. Chemical Shift of Glycosidic Anomeric Carbon, Proton, and Vicinal Coupling Constant JH1−H2 (
1H and 13C NMR,
D2O)
aDetermined via 1H NMR analysis of puriﬁed glycosides.
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neighboring H2 proton. The values of 3.6−4.0 Hz correspond
to α-glucosides, whereas β-glucosides show larger coupling
constants of 7.8−8.4 Hz, thus, conﬁrming the expected
stereoselective formation of α- and β-isomers by
TtSPP_R134A and UGT-76G1Sr, respectively. Finally, the
glycosidic anomeric carbon signals are observable as a singlet at
δ 98.2−101.6 and 101.1−102.6 ppm, respectively (13C NMR,
D2O).
Upon coupling of racemic cis-3-hydroxy-β-lactams 8 with
optically pure glucose, two cis-diastereomers (R,R)-9-G and
(S,S)-9-G might be expected as enzymes are chiral catalysts
and might therefore discriminate between either of the two
enantiomeric acceptor substrates. Indeed, from the analysis of
the NMR data presented in Table 3, it becomes clear that one
single product is obtained after α-glucosylation with
TtSPP_R134A. On the other hand, a very low enantioselec-
tivity was observed in the formation of two isomeric β-
glycosides 9-βG using the UGT-76G1Sr/SuSy system (dr =
36:64−44:56, as determined via 1H NMR). It should be noted,
however, that these values are determined after the isolation of
glycosides, implying the possibility that the recovery of the two
diastereomers during puriﬁcation might not be equal. On the
basis of the low concentration of product, though, compared to
the amount of non-reacted starting material, sucrose, fructose,
UDP, and UDP-glucose in the crude mixture, assessment of
the diastereomeric ratios based on the crude NMR data is not
reliable and practically infeasible.
In the literature, some examples of glycosyltransferases
catalyzing glycosylation reactions with high enantioselectivity
are reported, though the reaction conditions such as
temperature, (co-)solvent, enzyme formulation, additives, etc.
clearly aﬀect the isomeric ratios obtained.68 Similarly, the β-
glycosylation of compound 8a at 32 °C with acetone as a
cosolvent was found to furnish a more or less equimolar
mixture of isomers, whereas a higher selectivity was observed
upon incubation at 40 °C in combination with DMSO (dr =
44/56 and 71/29, respectively). A more detailed study on the
inﬂuence of reaction conditions on the enantioselectivity of
transferase-catalyzed transformations has not been published
yet and could thus constitute a suitable topic for prospective
research. Anyhow, it can be concluded that α-glucosylation of
cis-3-hydroxy-β-lactams 8 with TtSPP_R134A takes place with
a high enantioselectivity, and thus forms an eﬃcient route
toward optically pure α-glucosides 9-αG, while opening up the
opportunity to synthesize the corresponding chiral alcohols 8.
■ CONCLUSIONS
Glycosylation can have a profound impact on a compound’s
solubility, activity, and bioavailability. Preparing glycosylated
molecules is, however, far from trivial. In this work, three cis-3-
hydroxy-β-lactams were chemically synthesized via three
straightforward steps, after which the potential of two
carbohydrate-active enzymes for the production of their
corresponding α- or β-glucosides was evaluated. These
enzymes, which were selected based on their somewhat
promiscuous nature, successfully catalyzed the intended
reactions, albeit with low activity in comparison to the
reported activities on other, less demanding substrates.
However, the limited reaction rate is not surprising considering
the bulky and rigid structure of these β-lactams, and was
nonetheless suﬃcient to enable the production of six novel
glucosides at a preparative scale and their subsequent isolation
in analytically pure form. These ﬁndings highlight the potential
of the T. thermosaccharolyticum mutant phosphorylase and the
S. rebaudiana glycosyltransferase as promising catalysts for the
glucosylation of challenging molecules in general, and of cis-3-
hydroxy-β-lactams in particular. Furthermore, the glucosyl
moiety is transferred from the cheap and renewable sucrose
with superior regio- and stereoselectivity (and even enantio-
selectivity for α-glucosylation) without the need for any
protection or deprotection steps. Overall, the complimentary
use of classical organic synthesis and biocatalysis for
glycosylation reactions was once again shown to provide
major advantages within the framework of green chemistry.
■ EXPERIMENTAL PART
General Methods. Commercially available solvents and
reagents were purchased from common chemical suppliers and
used without further puriﬁcation. 1H NMR and 13C NMR
spectra were recorded at 400 and 100 MHz (Bruker Avance
III-400), respectively, in deuterated solvents with tetramethyl-
silane as the internal standard. IR spectra were obtained from
samples in neat form with an attenuated total reﬂectance
(ATR) accessory with a PerkinElmer Spectrum BX FT-IR or a
Shimadzu IRAﬃnity-1S WL FT-IR spectrophotometer. Melt-
ing points were measured using a Koﬂer bench, type WME
Heizbank of Wagner & Munz. High-performance liquid
chromatography (HPLC) and HPLC-MS analyses were
performed on an Agilent 1200 series HPLC system ﬁtted
with an Ascentis Express C18 column (particle size 2.7 μm,
length 30 mm, internal diameter 4.6 mm) and connected to a
UV−vis detector and an Agilent 1100 series LC/MSD-type SL
mass spectrometer (ESI, 70 eV) using a mass-selective single-
quadrupole detector. A mixture of acetonitrile/water (5 mM
NH4OAc) was used as the eluent. High-resolution electron
spray (ES-TOF) mass spectra were obtained with Agilent
Technologies 6210 Series Time of Flight. Automated column
chromatography was performed on a Büchi Reveleris X2 ﬂash
chromatography system (normal phase) or Grace Reveleris X1
ﬂash chromatography system (reversed phase), using Reveleris
C18 or Reveleris silica cartridges. Centrifugation for harvesting
cultures or performing buﬀer exchange was carried out in a
Sorvall RC-6 Plus rotator. Cell extracts were sonicated in a
Branson 250 soniﬁer (output control 3, 50% duty cycle).
Synthesis of 3-Acetoxyazetidin-2-ones 14. The syn-
thesis of cis-3-acetoxy-1-benzyl-4-phenylazetidin-2-one 14c
serves as a general example for the synthesis of 3-
acetoxyazetidin-2-ones 14a, 14b (for details, see Table 1 of
section “Results and Discussion”).
In a ﬂask of 500 mL, 9.75 g (50 mmol) of (E)-N-
(benzylidene)benzylamine 12c, synthesized according to the
literature,51 was dissolved in 120 mL dry tetrahydrofuran
(THF), followed by the addition of 20.9 mL (150 mmol; 3
equiv) triethylamine. After cooling the reaction mixture to 0
°C using an ice bath, a solution of 8.0 mL (75 mmol; 1.5
equiv) of acetoxyacetyl chloride 13 in 30 mL of dry THF was
added dropwise. This mixture was then stirred for 16 h at room
temperature, whereupon the solvent was evaporated under
reduced pressure. The residue was dissolved in dichloro-
methane (300 mL), washed twice with 360 mL water, which
on its turn was extracted with 150 mL dichloromethane. Next,
the combined organic phases were dried over magnesium
sulfate. Filtration of the drying agent, evaporation of the
solvent, and ﬂash chromatography with petroleum ether/ethyl
acetate (2:1) eventually yielded 10.18 g (69%) cis-3-acetoxy-1-
benzyl-4-phenylazetidin-2-one 14c.
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cis-3-Acetoxy-1-benzyl-4-isopropylazetidin-2-one
14a. The spectral data are derived from the mixture of cis- and
trans-isomers (dr = 91:9). Only the major isomer (cis) is
described.
1H NMR (400 MHz, CDCl3): δ 0.83 and 0.97 (2 × 3H, 2 ×
d, J = 6.8 Hz, (CH3)2CH); 1.95 (1H, ∼octet, J = 6.8 Hz,
(CH3)2CH); 2.14 (3H, s, CH3CO); 3.44 (1H, d × d, J =
6.8, 5.0 Hz, OCHCH); 4.11 and 4.86 (2 × 1H, 2 × d, J = 15.1
Hz, N(HCH)); 5.89 (1H, d, J = 5.0 Hz, CHO); 7.21−7.23
and 7.29−7.38 (2H and 3H, 2 × m, CHarom). 13C NMR (100
MHz, CDCl3): δ 19.2 and 19.4 ((CH3)2CH); 20.7 (CH3C
O); 28.4 ((CH3)2CH); 46.0 (NCH2); 62.9 (OCHCH); 74.5
(CHO); 128.0, 128.2, and 128.9 (5 × HCarom); 135.1
(Carom,quat); 166.1 (NCO); 169.6 (CH3CO). MS (70
eV): m/z (%) 262 (M+ + 1, 24); 284 (M+ + Na, 27). High
resolution electrospray ionization mass spectrometry (HRMS
(ESI)) calculated for C15H20NO3
+: 262.1438 [M + H]+, found:
262.1440. Yellow oil. Rf = 0.16 (PE/EtOAc 4:1). Yield after
column chromatography (SiO2): 47%.
cis-3-Acetoxy-1-isopropyl-4-propylazetidin-2-one
14b. β-Lactam 14b was immediately used in the next reaction
step, as puriﬁcation proved to be impossible at this stage.
cis-3-Acetoxy-1-benzyl-4-phenylazetidin-2-one 14c.
The spectral data are in accordance with those reported in
the literature.69
Synthesis of 3-Hydroxyazetidin-2-ones 8. The syn-
thesis of cis-1-benzyl-3-hydroxy-4-phenylazetidin-2-one 8c
serves as an example for the synthesis of 3-hydroxyazetidin-
2-ones 8a and 8b.
In a ﬂask of 50 mL, 1.62 g (5.5 mmol) of cis-3-acetoxy-1-
benzyl-4-phenylazetidin-2-one 14c was dissolved in 30 mL of a
1:1-solution of methanol and water (2:1 for 8a). Potassium
carbonate (1.52 g, 11 mmol; 2 equiv) was added and the
reaction mixture was stirred for 1 h at reﬂux temperature.
Hereafter, methanol was evaporated and an extraction was
performed with 50 mL diethyl ether. The organic phase was
washed twice with 50 mL water, whereupon the aqueous phase
was extracted twice with 50 mL diethyl ether. After drying of
the combined organic phases using magnesium sulfate,
ﬁltration of the drying agent, evaporation of the solvent and
recrystallization from a mixture of ethyl acetate and hexane
(1:1), 0.86 g (62%) cis-1-benzyl-3-hydroxy-4-phenylazetidin-2-
one 8c was obtained.
cis-1-Benzyl-3-hydroxy-4-isopropylazetidin-2-one 8a.
1H NMR (400 MHz, CDCl3): δ 0.94 and 1.01 (2 × 3H, 2 × d,
J = 6.9 Hz, (CH3)2CH); 2.06 (1H, ∼octet, J = 6.9 Hz,
(CH3)2CH); 3.28 (1H, d × d, J = 6.9, 5.2 Hz, OCHCH); 4.09
(1H, d, J = 5.9 Hz, OH); 4.11 and 4.81 (2 × 1H, 2 × d, J =
15.1 Hz, N(HCH)); 4.88 (1H, d × d, J = 5.9, 5.2 Hz, CHO);
7.20−7.22 and 7.27−7.37 (2H and 3H, 2 × m, CHarom). 13C
NMR (100 MHz, CDCl3): δ 19.4 and 19.9 ((CH3)2CH); 28.5
((CH3)2CH); 45.8 (NCH2); 64.6 (OCHCH); 75.9 (CHO);
127.8, 128.2, and 128.8 (5 × HCarom); 135.4 (Carom,quat); 170.8
(CO). MS (70 eV): m/z (%) 220 (M+ + 1, 100). HRMS
(ESI) calculated for C13H18NO2
+: 220.1332 [M + H]+, found:
220.1334. White crystals. Yield after recrystallization from
EtOAc/hexane (1:1): 47%. Tm = 76 °C.
cis-3-Hydroxy-1-isopropyl-4-propylazetidin-2-one
8b. The spectral data are in accordance with those reported in
the literature.1
cis-1-Benzyl-3-hydroxy-4-phenylazetidin-2-one 8c.
The spectral data are in accordance with those reported in
the literature.70
Enzyme Production and Puriﬁcation. The genes for
mutant R134A of the T. thermosaccharolyticum sucrose 6′-
phosphate phosphorylase (TtSPP_R134A; UniProt ID
D9TT09), the A. caldus sucrose synthase (SuSy; UniProt ID
A0A059ZV61) and the S. rebaudiana UDP-glucosyltransferase
(UGT-76G1Sr; UniProt ID Q6VAB4) were ligated into
expression vectors, transformed in Escherichia coli and
expressed recombinantly as described in earlier work.64,65,71
Cells containing the expressed proteins were harvested by
centrifugation (20 000g, 5 min) and frozen overnight at −20
°C. Intracellular proteins were extracted by dissolving 5 g of
frozen pellet in 25 mL of lysis buﬀer consisting of 50 mM 3-
(N-morpholino)propanesulfonic acid (MOPS), 100 μM
phenylmethylsulfonyl ﬂuoride, 1 mg/mL lysozyme, pH 7.0.
In the case of glucosyltransferase, MOPS was replaced by 50
mM sodium phosphate and 500 mM NaCl, pH 7.4. After
incubation on ice for 30 min, the extract was exposed three
times for 3 min of sonication and centrifuged to remove the
insoluble fraction (20 000g, 30 min, 4 °C). Extracts containing
sucrose synthase were used as such, while those containing
sucrose 6′-phosphate phosphorylase were subjected to heat
treatment (60 °C, 1 h) and centrifuged again. Extracts
containing the glucosyltransferase were further puriﬁed by
means of nickel−nitrilotriacetic acid aﬃnity chromatography in
gravity-ﬂow columns as described by the supplier (MCLab).
Subsequently, the buﬀer was exchanged to 50 mM MOPS, pH
7.0, in 30 kDa Amicon Ultra centrifugal ﬁlters (Merck).
The protein concentration was determined in triplicate using
the BCA Protein Assay kit (Pierce) with bovine serum albumin
as a standard.
Enzyme Activity Determination. The activity of
TtSPP_R134A and SuSy was conﬁrmed by performing
reactions where sucrose is broken down (100 mM sucrose
and 100 mM phosphate for TtSPP_R134A; 200 mM sucrose
and 5 mM UDP for SuSy; 55 °C) and following the release of
reducing sugars using the BCA method. The color reagent was
prepared by combining 23 parts of a solution containing 1.5 g/
L 4,4′-dicarboxy-2,2′-biquinoline dipotassium salt and 62.3 g/
L anhydrous Na2CO3, one part of a solution composed of 23
g/L aspartic acid, 33 g/L anhydrous Na2CO3, and 7.3 g/L
CuSO4 and six parts ethanol. The reaction samples (25 μL)
were incubated with 150 μL color reagent for 30 min at 70 °C.
Absorbance was measured at 560 nm.
The activity of UGT-76G1Sr was conﬁrmed through a
colorimetric assay, where UDP released from UDP-glucose is
converted to UTP by pyruvate kinase (PK) using phosphoe-
nolpyruvate (PEP). This reaction generates pyruvate as well,
which is in turn reduced to lactate while oxidizing NADH to
NAD+ by lactate dehydrogenase (LDH).72 The assay mixture
consisted of 100 times diluted PK/LDH enzymes from rabbit
muscle (900−1400 U/mL LDH, 600−100 U/mL PK), 5 mM
MgCl2, 1.6 mg/mL bovine serum albumin, 0.3 mM NADH,
and 0.3 mM PEP. A solution containing UGT-76G1Sr and
substrates (100 μL; 10 mM UDP-glucose, 20 mM stevioside)
was added to the assay mixture (100 μL) and absorbance at
340 nm was measured continuously.
Small-Scale Reactions and Optimization of Reaction
Conditions. Small-scale reactions were carried out at 200 μL
scale in Eppendorf tubes. The α-glucosylation reactions
contained 1 M sucrose, 15 mM acceptor, 10% (v/v) organic
solvent, 0.1 mg/mL TtSPP_R134A, and 50 mM MOPS (pH
7.0), and were incubated at 55 °C. The β-glucosylation
reactions contained 200 mM sucrose, 15 mM acceptor, 10%
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(v/v) organic solvent, 0.2 mg/mL UGT-76G1Sr, 1 mg/mL
SuSy, and 50 mM MOPS (pH 7.0), and were incubated at 32
°C. A 1 μL sample was taken after 24 h, spotted on silica gel 60
F254 precoated plates (Merck) and analyzed by thin layer
chromatography using a mixture of EtOAc/MeOH/H2O
(30:5:4) as the eluent. Spots were visualized by charring
with 10% (v/v) H2SO4.
Reactions were optimized by assessing various solvents, i.e.,
2-phenylethanol, methanol, isobutanol, 2-methylbutan-2-ol,
acetone, methyl t-butyl ether, diethyl ether, and acetonitrile.
Additionally, the acceptor concentration was varied (5−30
mM).
Synthesis of 3-O-α-D-Glucopyranosyl-3-hydroxyazeti-
din-2-ones 9-αG and Downstream Processing. The
production of α-glucosides 9a-αG, 9b-αG, and 9c-αG was
carried out using mutant TtSPP_R134A at a scale of 100, 25,
or 50 mL, respectively. Each reaction contained 1 M sucrose,
10 v/v% acetone, 0.04−0.06 mg/mL TtSPP_R134A, 50 mM
MOPS buﬀer (pH 7.0), and 21 mM of acceptor 8a or 15 mM
of acceptor 8b or 8c. These reaction samples were incubated
for 8−22 days at 55 °C with a reﬂux condenser, and stirred
magnetically (IKA RCt Classic). The reaction samples (50 μL)
were inactivated by adding 50 μL acetonitrile and 50 μL
ultrapure water, followed by centrifugation. These samples
were analyzed by LC-MS (eluent: 10−100% CH3CN in water
(5 mM NH4OAc)).
The α-glucosides were ﬁrst puriﬁed by double extraction
with isopropyl alcohol, to which NaCl was added (300 mg/
mL) to obtain a biphasic system. The organic phase was
washed with water to remove any remaining sugars, followed
by evaporation under reduced pressure. The remaining
product was dissolved in methanol, ﬁltered for the removal
of leftover salts and evaporated again. Subsequently, automatic
column chromatography was performed (gradual increase in
polarity of the eluent: petroleum ether/EtOAc (100:0) to
petroleum ether/EtOAc (0:100) to EtOAc/MeOH/H2O
(30:5:4)). Minor impurities were ﬁnally removed via
preparative TLC.
cis-1-Benzyl-3-O-α-D-glucopyranosyl-3-hydroxy-4-
isopropylazetidin-2-one 9a-αG. 1H NMR (400 MHz,
D2O): δ 0.88 and 0.93 (2 × 3H, 2 × d, J = 6.8 Hz,
(CH3)2CH); 2.07 (1H, octet, J = 6.8 Hz, (CH3)2CH); 3.39
(1H, d × d, J = 9.9, 9.1 Hz, CHCHCH2OH); 3.56 (1H, d × d,
J = 9.9, 3.6 Hz, CHCHα); 3.56−3.72 (4H, m, CHiPr and
CHCHCH(HCH)OH); 3.78 (1H, d × d, J = 12.3, 2.2 Hz,
O(HCH)); 4.27 and 4.68 (2 × 1H, 2 × d, J = 15.6 Hz,
N(HCH)); 4.97 (1H, d, J = 5.0 Hz, CHCHiPr); 5.21 (1H, d, J
= 3.6 Hz, CHα); 7.26−7.28 and 7.31−7.41 (2H and 3H, 2 ×
m, CHarom).
13C NMR (100 MHz, D2O): δ 18.3 and 19.2
((CH3)2CH); 27.7 ((CH3)2CH); 45.7 (NCH2); 60.4
(OCH2); 64.1 (CH
iPr); 69.4 (CHCHCH2OH); 71.1
(CHCHα); 72.7 and 72.8 (CHCHCHCH2OH); 77.7
(CHCHiPr); 98.5 (CHα); 128.0, 128.1 and 129.0 (5 ×
HCarom); 135.0 (Carom,quat); 170.9 (CO). IR (ATR, cm−1):
νOH = 3348; νCO = 1730; νmax = 2916, 2849, 2322, 1406,
1078, 1032, 924, 702. MS (70 eV): m/z (%) 404 (M+ + Na,
39); 382 (M+ + 1, 100). HRMS (ESI): calculated for
C19H28NO7
+: 382.1860 [M + H]+, found: 382.1862. Yellow
oil. Rf = 0.5 (EtOAc/MeOH/H2O 30:5:4). Yield after normal
phase column chromatography (SiO2): 12%.
cis-3-O-α-D-Glucopyranosyl-3-hydroxy-1-isopropyl-4-
propylazetidin-2-one 9b-αG. 1H NMR (400 MHz, D2O): δ
0.91 (3H, t, J = 7.4 Hz, CH2CH3); 1.19 and 1.21 (2 × 3H, 2 ×
d, J = 6.8 Hz, CH(CH3)2); 1.35 (2H, sextet, J = 7.4 Hz,
CH2CH3); 1.71−1.77 (2H, m, CH2CH2CH3); 3.39 (1H, ∼t, J
= 9.6 Hz, CHCHCH2OH); 3.54 (1H, d × d, J = 9.6, 3.6 Hz,
CHCHα); 3.57−3.77 (4H, m, CH(CH3)2 and CHCHCH-
(HCH)OH); 3.80 (1H, d × d, J = 12.3, 2.1 Hz, O(HCH));
3.99 (1H, ∼q, J = 5.4 Hz, CHCHPr); 4.88 (1H, d, J = 5.4 Hz,
CHCHPr); 5.18 (1H, d, J = 3.6 Hz, CHα).
13C NMR (100
MHz, D2O): δ 13.5 (CH2CH3); 18.8 (CH2CH3); 18.9 and
20.7 ((CH3)2CH); 30.7 (CH2CH2CH3); 44.9 ((CH3)2CH);
57.6 (CHCHPr); 60.4 (OCH2); 69.3 (CHCHCH2OH); 71.2
(CHCHα); 72.67 and 72.70 (CHCHCHCH2OH); 76.7
(CHCHPr); 98.2 (CHα); 169.3 (CO). IR (ATR, cm−1):
νOH = 3339; νCO = 1726; νmax = 2922, 2851, 2108, 1452,
1155, 1103, 1024, 627. MS (70 eV): m/z (%) 356 (M+ + Na,
100); 334 (M+ + 1.59). Rf = 0.3 (EtOAc/MeOH/H2O
30:5:4). Yield after normal phase column chromatography and
preparative TLC (SiO2): 17%.
cis-1-Benzyl-3-O-α-D-glucopyranosyl-3-hydroxy-4-
phenylazetidin-2-one 9c-αG. 1H NMR (400 MHz, D2O): δ
1.84−1.88 and 3.20−3.22 (1H and 2H, 2 × m,
CHCHCHCH2OH); 3.16 (1H, d × d, J = 12.9, 1.9 Hz,
(HCH)O); 3.28 (1H, d × d, J = 12.9, 3.1 Hz, (HCH)O); 3.40
(1H, d × d, J = 9.1, 4.0 Hz, CHCHα); 4.14 (1H, d, J = 15.0
Hz, N(HCH)); 4.68 (1H, d, J = 15.0 Hz, N(HCH)); 4.91
(1H, d, J = 4.5 Hz, CHPh); 4.97 (1H, d, J = 4.0 Hz, CHα);
5.16 (1H, d, J = 4.5 Hz, CHCHPh); 7.18−7.22 (2H, m,
CHarom); 7.31−7.38 (6H, m, CHarom); 7.40−7.44 (2H, m,
CHarom).
13C NMR (100 MHz, D2O): δ 44.6 (NCH2); 59.5
(OCH2) ; 63 .0 (CHPh) ; 68 .1 , 72 .2 , and 72 .4
(CHCHCHCH2OH); 71.2 (CHCHα); 83.6 (CHCHPh);
101.6 (CHα); 128.2, 128.7, 128.8, 128.9, 129.0, and 129.2
(10 × HCarom); 132.9 and 134.1 (2 × Carom,quat); 169.7 (C
O). IR (ATR, cm−1): νOH = 3352; νCO = 1743; νmax = 2926,
1452, 1412, 1350, 1080, 1022, 772, 700. MS (70 eV): m/z (%)
416 (M+ + 1, 100). HRMS (ESI): calculated for C22H26NO7
+:
416.1704 [M + H]+, found: 416.1705. Rf = 0.4 (EtOAc/
MeOH/H2O 30:5:4). White crystals. Yield after normal phase
column chromatography and preparative TLC (SiO2): 3%.
Synthesis of 3-O-β-D-Glucopyranosyl-3-hydroxyazeti-
din-2-ones 9-βG and Downstream Processing. The β-
glucosides 9a-βG, 9b-βG, and 9c-βG were synthesized at 100
mL scale using 200 mM sucrose, 2 mM UDP, 15 mM 8a, 8b,
or 8c, 10% (v/v) acetone, 0.11−0.19 mg/mL UGT-76G1Sr,
0.31−0.36 mg/mL SuSy, and 50 mM MOPS buﬀer (pH 7.0).
The reaction samples were incubated at 32 °C in falcon tubes
with continuous shaking at 200 rpm for 2 (8b, 8c) or 6 (8a)
weeks. The reaction samples (50 μL) were inactivated by
adding 50 μL acetonitrile and 50 μL ultrapure water, followed
by centrifugation. These samples were analyzed by LC-MS
(eluent: 10−100% CH3CN in water (5 mM NH4OAc)).
The products were isolated by extraction and column
chromatography as described for the α-glucosides. Finally, any
remaining impurities were removed by reverse phase column
chromatography (C18) using a gradient of water and
acetonitrile as the eluent: CH3CN/H2O (0:100) to CH3CN/
H2O (100:0).
cis-1-Benzyl-3-O-β-D-glucopyranosyl-3-hydroxy-4-iso-
propylazetidin-2-one 9a-βG. The spectral data are derived
from the mixture of diastereomers (dr = 44:56).
1H NMR (400 MHz, D2O): δ 0.92−0.99 (2 × 6H, m, 2 ×
(CH3)2CH); 2.10 (2 × 1H, octet, J = 6.5 Hz, 2 × (CH3)2CH);
3.33−3.41 (2 × 1H, m, 2 × CHCHβ); 3.42−3.55 (2 × 3H, m,
2 × CHCHCHCHCHβ); 3.65−3.72 (2 × 1H, m, CHiPr);
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3.73−3.78 (2 × 1H, m, 2 × O(HCH)); 3.89−3.95 (2 × 1H,
m, 2 × O(HCH)); 4.34 (1H, d, JAB = 15.8 Hz, N(HCH));
4.36 (1H, d, JAB = 15.4 Hz, N(HCH)); 4.52 (1H, d, J = 7.9 Hz,
CHβ); 4.70 (1H, d, J = 7.8 Hz, CHβ); 4.73 (1H, d, JAB = 15.4
Hz, N(HCH)); 4.75 (1H, d, JAB = 15.8 Hz, N(HCH)); 5.08
(1H, d, J = 4.8 Hz, CHCHiPr); 5.14 (1H, d, J = 4.9 Hz,
CHCHiPr); 7.33−7.47 (2 × 5H, m, CHarom). 13C NMR (100
MHz, D2O): δ 18.0, 18.3, 18.8, and 19.1 (2 × (CH3)2CH);
27.5 ((CH3)2CH); 27.6 ((CH3)2CH); 45.8 (NCH2); 45.9
(NCH2); 60.7 (OCH2); 60.8 (OCH2); 64.7 (CH
iPr); 64.9
(CHiPr); 69.6, 69.7, 75.69, 75.71, 76.0, and 76.2 (2 ×
CHCHCHCHCHβ); 73.0 (CHCHβ); 73.2 (CHCHβ); 79.7
(CHCHiPr); 80.7 (CHCHiPr); 102.3 (CHβ); 102.6 (CHβ);
128.0, 128.1, 128.2, and 129.0 (2 × (5 × HCarom)); 135.09
(Carom,quat); 135.15 (Carom,quat); 170.68 (CO); 170.72 (C
O). IR (ATR, cm−1): νOH = 3356; νCO = 1724; νmax = 2927,
1680, 1415, 1227, 1078, 1043, 993, 419. MS (70 eV): m/z (%)
382 (M+ + 1, 100). HRMS (ESI): calculated for C19H28NO7
+:
382.1860 [M + H]+, found: 382.1863. Colorless oil. Rf = 0.4
(EtOAc/MeOH/H2O 30:5:4). Yield after column chromatog-
raphy (SiO2 and C18): 0.2%.
cis-3-O-β-D-Glucopyranosyl-3-hydroxy-1-isopropyl-4-
propylazetidin-2-one 9b-βG. The spectral data are derived
from the mixture of diastereomers (dr = 36:64).
1H NMR (400 MHz, D2O): δ 0.95 (2 × 3H, t, J = 7.3 Hz, 2
× CH2CH3); 1.24−1.31 (2 × 6H, m, 2 × (CH3)2CH); 1.33−
1.50 (2 × 2H, m, 2 × CH2CH3); 1.68−1.82 (2 × 2H, m, 2 ×
CH2CH2CH3); 3.35 (2 × 1H, d × d, J = 8.4, 8.1 Hz, 2 ×
CHCHβ); 3.38−3.55 (2 × 3H, m, 2 × CHCHCHCHCHβ);
3.72−3.84 (2 × (2 × 1H), m, 2 × CHiPr and 2 × O(HCH));
3.93 (2 × 1H, d, J = 12.2 Hz, O(HCH)); 4.00−4.05 (2 × 1H,
m, 2 × CHCHPr); 4.50 (1H, d, J = 8.1 Hz, CHβ); 4.66 (1H, d,
J = 8.1 Hz, CHβ); 5.01 (1H, d, J = 4.8 Hz, CHCHPr); 5.03
(1H, d, J = 4.8 Hz, CHCHPr). 13C NMR (100 MHz, D2O): δ
13.4 (CH2CH3); 13.5 (CH2CH3); 18.5 (CH2CH3); 18.7
(CH2CH3); 18.9 and 20.7 ((CH3)2CH); 19.0 and 20.6
((CH3)2CH); 30.6 (CH2CH2CH3); 30.9 (CH2CH2CH3);
45.0 ((CH3)2CH); 45.1 ((CH3)2CH); 58.5 (CHPr); 58.7
(CHPr); 60.7 (2 × OCH2); 69.58, 69.66, 75.66, 75.69, 75.9
and 76.2 (2 × CHCHCHCHCHβ); 73.0 (CHCHβ); 73.2
(CHCHβ); 79.4 (CHCHPr); 79.6 (CHCHPr); 102.2 (CHβ);
102.4 (CHβ); 168.8 (C = 0); 169.0 (C = 0). IR (ATR, cm
−1):
νOH = 3356; νCO = 1722; νmax = 2932, 1680, 1416, 1225,
1175, 1078, 1043, 419. MS (70 eV): m/z (%) 334 (M+ + 1,
100). Colorless oil. Rf = 0.38 (EtOAc/MeOH/H2O 30:5:4).
Yield after column chromatography (SiO2 and C18): 1.4%.
cis-1-Benzyl-3-O-β-D-glucopyranosyl-3-hydroxy-4-
phenylazetidin-2-one 9c-βG. The spectral data are derived
from the mixture of diastereomers (dr = 41:59).
1H NMR (400 MHz, D2O): δ 3.01 (1H, d × d, J = 8.8, 8.4
Hz, CHCHβ); 3.07 (1H, d × d, J = 8.5, 8.4 Hz, CHCHβ);
3.13−3.41 (2 × 3H, m, 2 × CHCHCHCHCHβ); 3.53 (1H, d
× d, J = 11.8, 5.5 Hz, O(HCH)); 3.70 (1H, d × d, J = 11.8, 5.7
Hz, O(HCH)); 3.73 (1H, d, J = 12.0 Hz, O(HCH)); 3.89
(1H, d, J = 12.0 Hz, O(HCH)); 4.10 (1H, d, J = 8.4 Hz, CHβ);
4.13 (1H, d, JAB = 14.8 Hz, N(HCH)); 4.17 (1H, d, JAB = 15.1
Hz, N(HCH)); 4.52 (1H, d, J = 8.4 Hz, CHβ); 4.72 (1H, d, JAB
= 14.8 Hz, N(HCH)); 4.73 (1H, d, JAB = 15.1 Hz, N(HCH));
4.91 (1H, d, J = 4.6 Hz, CHPh); 4.93 (1H, d, J = 4.3 Hz,
CHPh); 5.31 (1H, d, J = 4.6 Hz, CHCHPh); 5.37 (1H, d, J =
4.3 Hz, CHCHPh); 7.20−7.21, 7.32−7.35, and 7.41−7.43 (2
× 10H, 3 × m, 2 × (10 × HCarom)).
13C NMR (100 MHz,
D2O): δ 44.6 (NCH2); 44.7 (NCH2); 60.66 (OCH2); 60.72
(OCH2); 61.9 (CHPh); 62.6 (CHPh); 69.2, 69.5, 75.1, 75.5,
and 75.9 (2 × CHCHCHCHCHβ); 72.5 (CHCHβ); 72.8
(CHCHβ); 80.6 (CHCHPh); 82.3 (CHCHPh); 101.1 (CHβ);
102.6 (CHβ); 128.2, 128.4, 128.66, 128.68, 128.73, 128.75,
128.79, 128.9, and 128.98 (2 × (10 × HCarom)); 132.7
(Carom,quat); 133.3 (Carom,quat); 134.2 (2 × Carom,quat); 169.1
(CO); 169.3 (CO). IR (ATR, cm−1): νOH = 3341; νCO
= 1738; νmax = 2924, 1672, 1452, 1416, 1233, 1076, 1045, 700.
MS (70 eV): m/z (%) 416 (M+ + 1, 100). Colorless oil. Rf =
0.36 (EtOAc/MeOH/H2O 30:5:4). Yield after column
chromatography (SiO2 and C18): 1%.
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